Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/15459
Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain
Monge, Susana | Olmedo, Carmen | Alejos, Belén | Lapeña, María Fé | Sierra, María José | Limia, Aurora | COVID-19 Registries Study Group2 | Mazagatos, Clara ISCIII | Larrauri, Amparo ISCIII
Emerg Infect Dis. 2021 Oct;27(10):2595-2603.
We conducted a registries-based cohort study of long-term care facility residents >65 years of age offered vaccination against severe acute respiratory syndrome coronavirus 2 before March 10, 2021, in Spain. Risk for infection in vaccinated and nonvaccinated persons was compared with risk in the same persons in a period before the vaccination campaign, adjusted by daily-varying incidence and reproduction number. We selected 299,209 persons; 99.0% had >1 dose, 92.6% had 2 doses, and 99.8% of vaccines were Pfizer/BioNTech (BNT162b2). For vaccinated persons with no previous infection, vaccine effectiveness was 81.8% (95% CI 81.0%-82.7%), and 11.6 (95% CI 11.3-11.9) cases were prevented per 10,000 vaccinated/day. In those with previous infection, effectiveness was 56.8% (95% CI 47.1%-67.7%). In nonvaccinated residents with no previous infection, risk decreased by up to 81.4% (95% CI 73.3%-90.3%). Our results confirm vaccine effectiveness in this population and suggest indirect protection in nonvaccinated persons.
COVID-19 | SARS-CoV-2 | Spain | Coronavirus disease | Elderly | Indirect effects | Long-term care facilities | Respiratory infections | Severe acute respiratory syndrome coronavirus 2 | Transmissibility | Vaccination | Vaccine effectiveness | Viruses | Zoonoses
COVID-19 | SARS-CoV-2 | BNT162 Vaccine | COVID-19 Vaccines | Cohort Studies | Humans | Long-Term Care | RNA, Messenger | Spain | Vaccination
Files in this item
- DirectIndirectEffectiveness_mR ...